Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis

Status Completed

Clinical Trial Summary

The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).

Clinical Trial Description

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the progressive form of liver disease that can lead to cirrhosis and liver-related mortality in persons who drink little or no alcohol. Nonalcoholic steatohepatitis (NASH) represents the more severe end of this spectrum and is characterized by steatosis, ballooning degeneration and lobular inflammation with or without fibrosis. The etiology of NASH is not completely understood, but it is often associated with obesity, type 2 diabetes, hyperlipidemia and insulin resistance. Lipotoxicity, insulin resistance and oxidative stress appear to be central to the pathogenesis of NASH. Currently, there is no FDA approved treatment for NAFLD/NASH. Weight loss and exercise are the recommended but often difficult maintain these lifestyle changes in the long term and therefore therapeutic agents have been investigated. Ezetimibe is an LDL lowering agent that works through inhibition of the fat absorption from the small intestine. In this study, we propose to treat 50 patients with NASH with either Ezetimibe or placebo for 24 weeks. After an initial evaluation for insulin sensitivity, MRI liver fat distribution and liver biopsy, patients will receive either 10 mg/day of Ezetimibe or placebo. Patients will be monitored at regular intervals for symptoms of liver disease, side effects of Ezetimibe and serum biochemical and metabolic indices. At the end of 24-weeks, patients will have a repeat medical evaluation, liver MRI and liver biopsy. Pre and post treatment MRI-derived liver fat content, liver histology and insulin sensitivity will be compared. The primary end point of successful therapy will be improvement in hepatic steatosis measured by MRI. Secondary end points will be improvement in insulin sensitivity, liver histology and liver biochemistry. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Non Alcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT01766713
Study type	Interventional
Source	University of California, San Diego
Contact
Status	Completed
Phase	Phase 2
Start date	January 2013
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05480696` - Soluble Fibre Supplementation in NAFLD	Phase 1
Completed	`NCT04573543` - The Role of Immune Semaphorins in NAFLD
Completed	`NCT01695083` - Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Not yet recruiting	`NCT05605158` - Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis	Phase 3
Completed	`NCT01761370` - Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)	N/A
Completed	`NCT03432377` - Coffee Consumption and NASH in the French Population.
Withdrawn	`NCT03864835` - NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal	N/A
Completed	`NCT05357352` - Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Not yet recruiting	`NCT03803540` - Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis	Phase 1
Completed	`NCT02395900` - The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease	Phase 2/Phase 3
Completed	`NCT01791959` - The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis	Phase 2/Phase 3
Recruiting	`NCT05821010` - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis	Phase 2
Recruiting	`NCT03734510` - The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study	N/A
Recruiting	`NCT02721264` - Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.	N/A
Terminated	`NCT03883607` - Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)	Phase 2
Completed	`NCT03863574` - Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis	Phase 2
Recruiting	`NCT03377153` - The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease	N/A
Recruiting	`NCT03377140` - The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease	N/A
Active, not recruiting	`NCT04669158` - Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis	Phase 1/Phase 2
Recruiting	`NCT06176079` - Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease